This program has recently started

This program has recently started, but it may still be possible to register if only the orientation class has been missed. Please call us at 514-481-0317‬‬ to inquire, and fill out the form below to be added to our waiting list.
    You can select more than one option

After decades of stalled progress, a new wave of clinical research involving psychedelic compounds shows promising results for treating depression, addiction, PTSD, and other mental health conditions.

MDMA is at the forefront of this psychiatric research; A multinational clinical trial of MDMA-assisted treatment for PTSD is currently underway in Canada, the US, and Israel. Sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS), this research holds the potential to make MDMA available to the public as a medicine for use in conjunction with psychotherapy by 2023, revolutionizing treatment for one of humanity’s most debilitating forms of suffering.

This evening talk for the general public will use the presenter’s experiences as MDMA research therapists to introduce and explore this exciting new frontier in mental health care, including discussing drug effects, the accompanying psychotherapy protocol, and the MAPS research program.

After the presentation audience members will be invited to ask questions during an extended Q&A period.

Advance registration is required. This program can be attended alone or in conjunction with the presenters’ weekend program: Psychedelics 101 & 102 for Clinicians held November 2 & 3, also in Montreal.


Regular Admission: $20
Students: $15 (Please contact us for discount code)

Mindspace is committed to accessibility for its public events and programs. If the event cost is prohibitive for you please contact us so that we can make an effort to accommodate you, space permitting.

Event partners:


Ingmar Gorman, Ph.D.

Ingmar Gorman, Ph.D., is a psychologist who specializes in assisting populations who have had experiences with psychedelics and other psychoactive compounds. He is the Director of the Psychedelic Education and Continuing Care Program, where he leads groups, trainings, and works with individual clients. Dr. Gorman is also site co-principal Investigator and therapist on a Phase 3 clinical trial studying the potential psychotherapeutic utility of MDMA for post-traumatic stress disorder. He is a NIH funded fellow at New York University and a board member of Horizons Media, Inc., a not for-profit educational charity and organizer of the Horizons Conference: Perspectives on Psychedelics.

Elizabeth Nielson, Ph.D.

Dr. Elizabeth Nielson is a psychologist with a holistic, compassionate, and integrative approach to psychotherapy. She specializes in treating addictive and mood disorders with a blend of of mindfulness-based interventions, dialectical behavior therapy, psychodynamic therapy, community reinforcement and family training (CRAFT), and principles of psychedelic-assisted therapy. Dr. Nielson is part of the Experimental Therapeutics Research Laboratory at NYU Langone School of Medicine where she is a therapist on the psilocybin-assisted treatment for alcohol dependence trial and on the MDMA-assisted psychotherapy for PTSD clinical trials.